Search research articles
Contact Us
Filters
Showing results (151-160 of 218) with videos related to
Page
of 22
Sort By:
International Journal of Cancer
|
July 8, 2024
Influence of adjuvant therapies on organ-specific recurrence of cutaneous melanoma: A multicenter study on 1383 patients of the prospective DeCOG registry ADOReg
Sebastian A Wohlfeil, Leonie Kranzmann, Christel Weiß, et al.
British Journal of Cancer
|
February 14, 2018
Clinical outcome of concomitant vs interrupted BRAF inhibitor therapy during radiotherapy in melanoma patients
Markus Hecht, Friedegund Meier, Lisa Zimmer, et al.
Journal for Immunotherapy of Cancer
|
January 25, 2022
Clinical and molecular characteristics associated with response to therapeutic PD-1/PD-L1 inhibition in advanced Merkel cell carcinoma
Ivelina Spassova, Selma Ugurel, Linda Kubat, et al.
Science (New York, N.Y.)
|
September 12, 2015
Genomic correlates of response to CTLA-4 blockade in metastatic melanoma
Eliezer M Van Allen, Diana Miao, Bastian Schilling, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
March 22, 2025
Early termination does not negatively impact the outcome of adjuvant immunotherapy in melanoma
Dirk Tomsitz, Elisabeth Livingstone, Carmen Loquai, et al.
Frontiers in Oncology
|
October 8, 2021
Digital Quantification of Tumor PD-L1 Predicts Outcome of PD-1-Based Immune Checkpoint Therapy in Metastatic Melanoma
Jan-Malte Placke, Camille Soun, Jenny Bottek, et al.
Cancers
|
June 2, 2021
Discontinuation of BRAF/MEK-Directed Targeted Therapy after Complete Remission of Metastatic Melanoma-A Retrospective Multicenter ADOReg Study
Henner Stege, Maximilian Haist, Michael Schultheis, et al.
European Journal of Cancer (Oxford, England : 1990)
|
July 24, 2023
Adjuvant treatment and outcome of stage III melanoma patients: Results of a multicenter real-world German Dermatologic Cooperative Oncology Group (DeCOG) study
Georg C Lodde, Jessica Hassel, Lena M Wulfken, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 26, 2026
Treatment patterns in geriatric patients with melanoma and the effect of age on the efficacy of immunotherapy: Analysis from the real-world multicenter registry ADOREG
Konstantinos Lallas, Lena Nanz, Selma Ugurel, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 26, 2026
Real-world data on anti-PD-1 plus lenvatinib as a treatment option in pretreated advanced melanoma patients - a retrospective DeCOG study
Lea Jessica Albrecht, Jana Garnier, Anne Zaremba, et al.
Page
of 22
Search research articles
Search
Showing results (151-160 of 218) with videos related to
Sort By:
Page
of 22
International Journal of Cancer
|
July 8, 2024
Influence of adjuvant therapies on organ-specific recurrence of cutaneous melanoma: A multicenter study on 1383 patients of the prospective DeCOG registry ADOReg
Sebastian A Wohlfeil, Leonie Kranzmann, Christel Weiß, et al.
British Journal of Cancer
|
February 14, 2018
Clinical outcome of concomitant vs interrupted BRAF inhibitor therapy during radiotherapy in melanoma patients
Markus Hecht, Friedegund Meier, Lisa Zimmer, et al.
Journal for Immunotherapy of Cancer
|
January 25, 2022
Clinical and molecular characteristics associated with response to therapeutic PD-1/PD-L1 inhibition in advanced Merkel cell carcinoma
Ivelina Spassova, Selma Ugurel, Linda Kubat, et al.
Science (New York, N.Y.)
|
September 12, 2015
Genomic correlates of response to CTLA-4 blockade in metastatic melanoma
Eliezer M Van Allen, Diana Miao, Bastian Schilling, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
March 22, 2025
Early termination does not negatively impact the outcome of adjuvant immunotherapy in melanoma
Dirk Tomsitz, Elisabeth Livingstone, Carmen Loquai, et al.
Frontiers in Oncology
|
October 8, 2021
Digital Quantification of Tumor PD-L1 Predicts Outcome of PD-1-Based Immune Checkpoint Therapy in Metastatic Melanoma
Jan-Malte Placke, Camille Soun, Jenny Bottek, et al.
Cancers
|
June 2, 2021
Discontinuation of BRAF/MEK-Directed Targeted Therapy after Complete Remission of Metastatic Melanoma-A Retrospective Multicenter ADOReg Study
Henner Stege, Maximilian Haist, Michael Schultheis, et al.
European Journal of Cancer (Oxford, England : 1990)
|
July 24, 2023
Adjuvant treatment and outcome of stage III melanoma patients: Results of a multicenter real-world German Dermatologic Cooperative Oncology Group (DeCOG) study
Georg C Lodde, Jessica Hassel, Lena M Wulfken, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 26, 2026
Treatment patterns in geriatric patients with melanoma and the effect of age on the efficacy of immunotherapy: Analysis from the real-world multicenter registry ADOREG
Konstantinos Lallas, Lena Nanz, Selma Ugurel, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 26, 2026
Real-world data on anti-PD-1 plus lenvatinib as a treatment option in pretreated advanced melanoma patients - a retrospective DeCOG study
Lea Jessica Albrecht, Jana Garnier, Anne Zaremba, et al.
Page
of 22